|Bid||249.95 x 100|
|Ask||254.70 x 100|
|Day's Range||246.12 - 254.37|
|52 Week Range||223.02 - 333.65|
|PE Ratio (TTM)||15.87|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday. Roche said it was investigating a case of Progressive Multifocal Leukoencephalopathy (PML) in a patient previously being treated for three years with Biogen Inc’s Tysabri and who had received a single dose of Ocrevus in February. Roche is trying to determine the source of the illness but MS drugs that suppress the immune system can increase the risk of serious infections.
Bioverativ stock popped Wednesday after the Biogen spinoff announced a $400 million acquisition of True North Therapeutics.